Cardiometabolic Risk, Part 1: Chemotherapy and Radiotherapy - Old Foes Still Threatening Cancer Survivors?

Maja Vestmø Maraldo, Alessandro Andreis, Ilenia Iamundo de Cumis, Marzia Cerrato, Angelisa Vella, Umberto Ricardi, Mario Levis

Abstract

Long-term cancer survivors are at high risk of developing cardiac complications from the treatments, both systemic agents and thoracic irradiation, received to cure the primary tumor. Modern advances, particularly in the field of radiotherapy, aim to reduce the risk of cardiovascular disease. Also, new diagnostic tools increasingly improve their efficacy in early detection of the preclinical treatment-induced cardiac damage. In this review, we summarize the mechanisms of radiotherapy- and chemotherapy-induced cardiac injury, the available clinical data, the strategies to mitigate cardiac exposure with modern radiotherapy and the current diagnostic tools for an early detection and prompt management of these complications in long-term cancer survivors.

OriginalsprogEngelsk
TitelCardiometabolic Risk, Part 1: Chemotherapy and Radiotherapy - Old Foes Still Threatening Cancer Survivors?
Antal sider15
Vol/bind54
Publikationsdato2021
Sider115-129
DOI
StatusUdgivet - 2021
NavnFrontiers of Hormone Research
ISSN0301-3073

Fingeraftryk

Dyk ned i forskningsemnerne om 'Cardiometabolic Risk, Part 1: Chemotherapy and Radiotherapy - Old Foes Still Threatening Cancer Survivors?'. Sammen danner de et unikt fingeraftryk.

Citationsformater